Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
15.97
+0.21 (1.37%)
Oct 2, 2025, 3:46 PM EDT - Market open
Roivant Sciences Revenue
Roivant Sciences had revenue of $2.17M in the quarter ending June 30, 2025, a decrease of -72.84%. This brings the company's revenue in the last twelve months to $23.23M, down -35.86% year-over-year. In the fiscal year ending March 31, 2025, Roivant Sciences had annual revenue of $29.05M, down -11.19%.
Revenue (ttm)
$23.23M
Revenue Growth
-35.86%
P/S Ratio
468.96
Revenue / Employee
$30,977
Employees
750
Market Cap
10.90B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 29.05M | -3.66M | -11.19% |
Mar 31, 2024 | 32.71M | 1.18M | 3.75% |
Mar 31, 2023 | 31.53M | -23.76M | -42.97% |
Mar 31, 2022 | 55.29M | 31.49M | 132.34% |
Mar 31, 2021 | 23.80M | -43.89M | -64.85% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ROIV News
- 7 days ago - Roivant Sciences Ltd. (ROIV) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 7 days ago - Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 9 days ago - Roivant Sciences Ltd. (ROIV) Q1 2024 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Roivant Sciences Ltd. - Special Call - Seeking Alpha
- 15 days ago - Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial - Benzinga
- 15 days ago - Roivant, Priovant Therapeutics' rare skin and muscle disease drug shows promise in trial - Reuters
- 15 days ago - Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) - GlobeNewsWire
- 20 days ago - Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List - GlobeNewsWire